Sarah Kesler, MD
Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1588018725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 241 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$814
- Amgen$580
- BETA Bionics, Inc.$471
- Dexcom, Inc.$369
- Lilly USA, LLC$365
- Xeris Pharmaceuticals, Inc.$254
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,76099%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $814 |
| Amgen | 22 | $580 |
| BETA Bionics, Inc. | 10 | $471 |
| Dexcom, Inc. | 13 | $369 |
| Lilly USA, LLC | 22 | $365 |
| Xeris Pharmaceuticals, Inc. | 13 | $254 |
| AstraZeneca | 8 | $209 |
| Boehringer Ingelheim | 10 | $206 |
| Bayer | 10 | $191 |
| Sanofi-aventis U.S. LLC | 9 | $181 |
| Corcept Therapeutics | 7 | $162 |
| Antares Pharma, Inc. | 5 | $109 |
| Recordati_rare_diseases_inc. | 5 | $97 |
| Pfizer | 5 | $95 |
| Amneal Pharmaceuticals LLC | 5 | $91 |
| AbbVie | 3 | $67 |
| Ascensia Diabetes Care US Inc. | 4 | $66 |
| IBSA Pharma Inc. | 4 | $61 |
| Tandem Diabetes Care, Inc. | 2 | $59 |
| Mannkind Corporation | 2 | $58 |
| Medtronic | 3 | $46 |
| Insulet Corporation | 2 | $45 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Radius Health, Inc. | 1 | $26 |
| Theratechnologies Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $18 |
| Merck | 1 | $17 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$1,053
- DEXCOM G6 TRANSMITTER$126
- TEPEZZA$125
- EVENITY$120
How this compares
$4,811 in reported general payments places this provider in the 55th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 366 | $512,909 |
| MounjaroTirzepatide | 199 | $274,149 |
| JardianceEmpagliflozin | 199 | $211,926 |
| TrulicityDulaglutide | 56 | $91,869 |
| ForteoTeriparatide | 20 | $84,088 |
| FarxigaDapagliflozin Propanediol | 43 | $64,987 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $48,253 |
| TradjentaLinagliptin | 41 | $32,600 |
| RybelsusSemaglutide | 26 | $31,305 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $26,467 |
| Repatha SureclickEvolocumab | 32 | $25,444 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $24,141 |
| KerendiaFinerenone | 30 | $22,708 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $18,002 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $14,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $814 | $568,356406 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Baqsimi, Humalog | $365 | $460,593311 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $206 | $257,758252 claims |
| AstraZenecaFarxiga | $209 | $64,98743 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $181 | $26,46735 claims |
| BayerKerendia | $191 | $22,70830 claims |
| PfizerLevoxyl | $95 | $6,48199 claims |
| AbbVieSynthroid | $67 | $4,76042 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $91 | $1,834234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Marrero
- Marideli ScanlanMarrero$444K
- Tilak MallikMarrero$51K
- Alejandra Riera GonzalezMarrero$7K
- Amy VarugheseMarrero$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.